New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Kroger settles an opioid lawsuit in Kentucky for $110 million. The U.S. builds a bird flu vaccine stockpile. Shanghai permits ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...